Drug Trial Radar · NCT01187966
Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease
Last checked: Nov 19, 2026Latest source record: Aug 24, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
669
Actual
Start
Jan 2007
Primary completion
Oct 2008
Study completion Feb 2009
Sponsor
- Lead sponsor
- Newron Pharmaceuticals SPAIndustry
- Sponsor type
- Industry
- First posted
- Aug 24, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of two doses of safinamide (50 and 100 mg/day, p.o.), compared to placebo, as add-on therapy in patients with idiopathic Parkinson's disease with motor fluctuations who are currently receiving a stable dose of levodopa.
Conditions
- Parkinson's Disease
Interventions
SafinamideDrug
SafinamideDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Increase in mean daily "on" timeTime frame: baseline to endpoint
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.